WallStreetZenWallStreetZen

NASDAQ: AVTE
Aerovate Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for AVTE

Based on 2 analysts offering 12 month price targets for Aerovate Therapeutics Inc.
Min Forecast
$27.00+24.6%
Avg Forecast
$31.50+45.36%
Max Forecast
$36.00+66.13%

Should I buy or sell AVTE stock?

Based on 2 analysts offering ratings for Aerovate Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AVTE stock forecasts and price targets.

AVTE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Guggenheim
Top 5%
96
Strong BuyInitiates Coverage On$36.00+66.13%2023-03-01
BTIG
Top 14%
87
Strong BuyUpgrades$27.00+24.60%2022-12-06

1 of 1

Forecast return on equity

Is AVTE forecast to generate an efficient return?
Company
N/A
Industry
-0.01%
Market
28.77%

Forecast return on assets

Is AVTE forecast to generate an efficient return on assets?
Company
N/A
Industry
0.05%

AVTE earnings per share forecast

What is AVTE's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$2.10
Avg 2 year Forecast
-$2.05
Avg 3 year Forecast
-$3.39

AVTE revenue forecast

What is AVTE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$36.7M
Avg 2 year Forecast
$129.1M
Avg 3 year Forecast
$323.8M

AVTE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVTE$21.67$31.50+45.36%Strong Buy
ALDX$9.06$18.67+106.04%Strong Buy
TRDA$16.20$18.00+11.11%Hold
BTAI$18.25$42.17+131.05%Buy
MOR$3.94$15.00+280.71%Buy

Aerovate Therapeutics Stock Forecast FAQ

Is Aerovate Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AVTE) stock is to Strong Buy AVTE stock.

Out of 2 analysts, 2 (100%) are recommending AVTE as a Strong Buy, 0 (0%) are recommending AVTE as a Buy, 0 (0%) are recommending AVTE as a Hold, 0 (0%) are recommending AVTE as a Sell, and 0 (0%) are recommending AVTE as a Strong Sell.

If you're new to stock investing, here's how to buy Aerovate Therapeutics stock.

What is AVTE's earnings growth forecast for 2023-2025?

(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.49%.

Aerovate Therapeutics's earnings in 2023 is -$44,712,000.On average, 3 Wall Street analysts forecast AVTE's earnings for 2023 to be -$51,670,653, with the lowest AVTE earnings forecast at -$54,377,211, and the highest AVTE earnings forecast at -$48,718,045. On average, 2 Wall Street analysts forecast AVTE's earnings for 2024 to be -$50,440,400, with the lowest AVTE earnings forecast at -$51,916,704, and the highest AVTE earnings forecast at -$48,718,045.

In 2025, AVTE is forecast to generate -$83,411,197 in earnings, with the lowest earnings forecast at -$100,880,799 and the highest earnings forecast at -$65,941,596.

What is AVTE's revenue growth forecast for 2026-2028?

(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.8%.

Aerovate Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast AVTE's revenue for 2026 to be $903,498,281, with the lowest AVTE revenue forecast at $903,498,281, and the highest AVTE revenue forecast at $903,498,281. On average, 2 Wall Street analysts forecast AVTE's revenue for 2027 to be $3,177,105,446, with the lowest AVTE revenue forecast at $2,338,958,239, and the highest AVTE revenue forecast at $4,015,277,258.

In 2028, AVTE is forecast to generate $7,966,138,434 in revenue, with the lowest revenue forecast at $4,005,213,783 and the highest revenue forecast at $11,927,063,086.

What is AVTE's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: AVTE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.05%.

What is AVTE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AVTE price target, the average AVTE price target is $31.50, with the highest AVTE stock price forecast at $36.00 and the lowest AVTE stock price forecast at $27.00.

On average, Wall Street analysts predict that Aerovate Therapeutics's share price could reach $31.50 by Mar 1, 2024. The average Aerovate Therapeutics stock price prediction forecasts a potential upside of 45.36% from the current AVTE share price of $21.67.

What is AVTE's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: AVTE) Aerovate Therapeutics's current Earnings Per Share (EPS) is -$1.57. On average, analysts forecast that AVTE's EPS will be -$2.10 for 2023, with the lowest EPS forecast at -$2.21, and the highest EPS forecast at -$1.98. On average, analysts forecast that AVTE's EPS will be -$2.05 for 2024, with the lowest EPS forecast at -$2.11, and the highest EPS forecast at -$1.98. In 2025, AVTE's EPS is forecast to hit -$3.39 (min: -$4.10, max: -$2.68).

What is AVTE's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: AVTE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.